FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292787473> ?p ?o ?g. }

• W4292787473 endingPage "827" @default.
• W4292787473 startingPage "813" @default.
• W4292787473 abstract "Although the Pfizer-BioNTech (BNT162b2), Oxford-AstraZeneca (ChAdOx1 nCoV-19), Sinopharm (BBIBP-CorV), and Sputnik V coronavirus disease 2019 (COVID-19) vaccines have been granted emergency approval in many nations, their safety has never been studied and compared in one community-based study. This study aimed to investigate and compare the incidence, nature, severity, and predictors of adverse events following immunization (AEFIs) with COVID-19 vaccines.This was a prospective observational study conducted in Jordan between 1 January and 21 September 2021. A team of pharmacists and nurses (n = 407) collected the local and systemic AEFIs of four COVID-19 vaccines by prospectively contacting participants registered in the national vaccination program platform. A red-flag technology was inserted to classify and track rare and serious AEFIs.This study included 658,428 participants who were vaccinated with 1,032,430 doses; 610,591, 279,606, 140,843, and 1390 participants received the first and second doses of the BNT162b2, BBIBP-CorV, ChAdOx1 nCoV-19, and Sputnik V vaccines, respectively. The overall incidence of AEFIs was 28.8%, and the overall rates of systemic, local, and immediate hypersensitivity AEFIs were 22.2%, 18.8%, and 0.5%, respectively. The highest proportions of immediate hypersensitivity AEFIs and systemic AEFIs were reported after administration of the Sputnik V vaccine and ChAdOx1 nCoV-19 first dose, respectively. The most severe AEFIs were reported after ChAdOx1 nCoV-19 first dose and BNT162b2 second dose. The hospitalization and mortality rates after vaccination were 20 in 10,000 and 1 in 10,000, respectively. Based on red-flag tracking, the top three outcome events were lymphadenopathy (157.9/100,000), anxiety disorders (136.6/100,000), and lower respiratory tract infection (100.9/100,000), with Guillain-Barré syndrome (1.8/100,000), vasculitis (3.0/100,000), and myopericarditis (4.8/100,000) being the least common.The incidence rates of local, systemic, and immediate hypersensitivity AEFIs of four COVID-19 vaccines occur frequently. High incidence rates of rare and serious AEFIs were reported in this study. Younger participants, females, those who had previously had COVID-19, and smokers were more likely to encounter AEFIs." @default.
• W4292787473 created "2022-08-23" @default.
• W4292787473 creator A5000394845 @default.
• W4292787473 creator A5012242890 @default.
• W4292787473 creator A5017007976 @default.
• W4292787473 creator A5020516352 @default.
• W4292787473 creator A5023763294 @default.
• W4292787473 creator A5040109123 @default.
• W4292787473 creator A5040344137 @default.
• W4292787473 creator A5041659504 @default.
• W4292787473 creator A5045338487 @default.
• W4292787473 creator A5053099585 @default.
• W4292787473 creator A5056443210 @default.
• W4292787473 creator A5056642122 @default.
• W4292787473 creator A5061116085 @default.
• W4292787473 creator A5070016339 @default.
• W4292787473 creator A5071673316 @default.
• W4292787473 creator A5076655521 @default.
• W4292787473 creator A5078354324 @default.
• W4292787473 creator A5082159992 @default.
• W4292787473 creator A5084892110 @default.
• W4292787473 creator A5086113790 @default.
• W4292787473 creator A5089540682 @default.
• W4292787473 creator A5090065847 @default.
• W4292787473 date "2022-08-23" @default.
• W4292787473 modified "2023-10-17" @default.
• W4292787473 title "Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan" @default.
• W4292787473 cites W1765287762 @default.
• W4292787473 cites W2131643987 @default.
• W4292787473 cites W2147146850 @default.
• W4292787473 cites W2556574204 @default.
• W4292787473 cites W2618219544 @default.
• W4292787473 cites W3111255098 @default.
• W4292787473 cites W3127329393 @default.
• W4292787473 cites W3130815000 @default.
• W4292787473 cites W3153726103 @default.
• W4292787473 cites W3153840436 @default.
• W4292787473 cites W3157162195 @default.
• W4292787473 cites W3158373340 @default.
• W4292787473 cites W3165935379 @default.
• W4292787473 cites W3169184291 @default.
• W4292787473 cites W3172905784 @default.
• W4292787473 cites W3176817209 @default.
• W4292787473 cites W3184492194 @default.
• W4292787473 cites W3189030052 @default.
• W4292787473 cites W3195586393 @default.
• W4292787473 cites W3199545736 @default.
• W4292787473 cites W3200977152 @default.
• W4292787473 cites W3201008724 @default.
• W4292787473 cites W3201227151 @default.
• W4292787473 cites W3210110680 @default.
• W4292787473 cites W4205609727 @default.
• W4292787473 cites W4225723258 @default.
• W4292787473 cites W4226310502 @default.
• W4292787473 cites W4226316060 @default.
• W4292787473 doi "https://doi.org/10.1007/s40261-022-01191-1" @default.
• W4292787473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35999428" @default.
• W4292787473 hasPublicationYear "2022" @default.
• W4292787473 type Work @default.
• W4292787473 citedByCount "6" @default.
• W4292787473 countsByYear W42927874732022 @default.
• W4292787473 countsByYear W42927874732023 @default.
• W4292787473 crossrefType "journal-article" @default.
• W4292787473 hasAuthorship W4292787473A5000394845 @default.
• W4292787473 hasAuthorship W4292787473A5012242890 @default.
• W4292787473 hasAuthorship W4292787473A5017007976 @default.
• W4292787473 hasAuthorship W4292787473A5020516352 @default.
• W4292787473 hasAuthorship W4292787473A5023763294 @default.
• W4292787473 hasAuthorship W4292787473A5040109123 @default.
• W4292787473 hasAuthorship W4292787473A5040344137 @default.
• W4292787473 hasAuthorship W4292787473A5041659504 @default.
• W4292787473 hasAuthorship W4292787473A5045338487 @default.
• W4292787473 hasAuthorship W4292787473A5053099585 @default.
• W4292787473 hasAuthorship W4292787473A5056443210 @default.
• W4292787473 hasAuthorship W4292787473A5056642122 @default.
• W4292787473 hasAuthorship W4292787473A5061116085 @default.
• W4292787473 hasAuthorship W4292787473A5070016339 @default.
• W4292787473 hasAuthorship W4292787473A5071673316 @default.
• W4292787473 hasAuthorship W4292787473A5076655521 @default.
• W4292787473 hasAuthorship W4292787473A5078354324 @default.
• W4292787473 hasAuthorship W4292787473A5082159992 @default.
• W4292787473 hasAuthorship W4292787473A5084892110 @default.
• W4292787473 hasAuthorship W4292787473A5086113790 @default.
• W4292787473 hasAuthorship W4292787473A5089540682 @default.
• W4292787473 hasAuthorship W4292787473A5090065847 @default.
• W4292787473 hasBestOaLocation W42927874731 @default.
• W4292787473 hasConcept C126322002 @default.
• W4292787473 hasConcept C197934379 @default.
• W4292787473 hasConcept C203014093 @default.
• W4292787473 hasConcept C22070199 @default.
• W4292787473 hasConcept C2779134260 @default.
• W4292787473 hasConcept C3008058167 @default.
• W4292787473 hasConcept C524204448 @default.
• W4292787473 hasConcept C71924100 @default.
• W4292787473 hasConceptScore W4292787473C126322002 @default.
• W4292787473 hasConceptScore W4292787473C197934379 @default.
• W4292787473 hasConceptScore W4292787473C203014093 @default.
• W4292787473 hasConceptScore W4292787473C22070199 @default.

• next